

1 **The cost of sleeping sickness vector control in the** 2 **Democratic Republic of the Congo**

3
4

5 Rian Snijders^{1,2,3}, Alexandra P.M. Shaw^{4, 5}, Richard Selby⁶, Inaki Tirados⁷, Paul R Bessell⁸,
6 Alain Fukinsia⁹, Erick Miaka⁹, Fabrizio Tediosi^{2,3}, Epcó Hasker¹, Marina Antillon^{2,3}

7
8

9 ¹Institute of Tropical Medicine Antwerp, Belgium

10 ²Swiss Tropical and Public Health Institute, Basel, Switzerland

11 ³University of Basel, Basel, Switzerland

12 ⁴University of Edinburgh, Edinburgh, UK

13 ⁵AP Consultants, Walworth Enterprise Centre, Andover, UK.

14 ⁶Sightsavers, 35 Perrymount Road, Haywards Heath, West Sussex, RH16 3BW, UK

15 ⁷Liverpool School of Tropical Medicine, Liverpool, UK

16 ⁸Independent consultant, Edinburgh, United Kingdom

17 ⁹Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Kinshasa,

18 Democratic Republic of the Congo

19

20 * Corresponding author:

21 E-mail: riansnijders@hotmail.com (RS)

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 Gambian human African trypanosomiasis (gHAT), a neglected tropical disease caused by a
25 parasite transmitted by tsetse flies, once inflicted over 30,000 annual cases and resulted in
26 half a million deaths in the late twentieth century. An international gHAT control program
27 has reduced cases to under 1,000 annually, encouraging the World Health Organization to
28 target the elimination of gHAT transmission by 2030. This requires adopting innovative
29 disease control approaches in foci where transmission persists. Since the last decade, case
30 detection and treatment, the mainstay of controlling the disease, is supplemented by vector
31 control using Tiny Targets, small insecticide-treated screens, which attract and kill tsetse. The
32 advantages of Tiny Targets lie in their relatively low cost, easy deployment, and
33 effectiveness.

34
35 The Democratic Republic of Congo (DRC), bearing 65% of the 799 gHAT cases reported
36 globally in 2022, introduced Tiny Targets in 2015. This study estimates the annual cost of
37 vector control using Tiny Targets in a health district in the DRC and identifies the main cost
38 drivers. Economic and financial costs, collected from the provider's perspective, were used to
39 estimate the average cost of tsetse control expressed as cost (i) per target used, (ii) per target
40 deployed, (iii) linear kilometre of river controlled, and (iv) square kilometres protected by
41 vector control. Sensitivity analyses were conducted on key parameters for results robustness.

42
43 The estimated annual economic cost for protecting an area of 1,925 km² was 120,000 USD.
44 This translates to 5.3 USD per target used each year, 11 USD per target deployed in the field,
45 573 USD per linear km treated, and 62 USD per km² protected. These costs in the DRC are
46 comparable to those in other countries. The study provides valuable information for

47 practitioners and policymakers aiding them in making rational, evidence-based decisions

48 regarding cost-effective strategies to control gHAT.

49

50

51 **Author Summary**

52 In the fight against Gambian human African trypanosomiasis (gHAT), a devastating disease
53 transmitted by tsetse flies, significant progress has been made through international efforts.
54 Despite the annual cases being reduced to under 1,000, the World Health Organization aims
55 to eliminate gHAT transmission by 2030. A key component of this strategy involves
56 innovative approaches, such as the use of Tiny Targets – small, cost-effective, insecticide-
57 treated screens that attract and kill tsetse flies. This study focuses on the Democratic Republic
58 of Congo (DRC), which bears a substantial burden of gHAT cases, estimating the annual cost
59 of vector control using Tiny Targets in a specific health district. The analysis, conducted
60 from the provider's perspective, reveals an annual economic cost of 120,000 USD for
61 protecting a 1,925 km² area. This translates to 5.3 USD per target used, 11 USD per target
62 deployed, 573 USD per linear km treated, and 62 USD per km² protected. These findings,
63 comparable to costs in other countries, offer valuable insights for practitioners and
64 policymakers, guiding evidence-based decisions on cost-effective strategies for gHAT
65 control.

66

67 **Introduction**

68

69 Sleeping sickness or Human African Trypanosomiasis (HAT) is a vector-borne parasitic
70 disease that caused several major outbreaks in sub-Saharan Africa, killing thousands of
71 people during the last epidemic of the 1990s. The disease is transmitted through the bite of an
72 infected tsetse fly (genus *Glossina*) and is almost always lethal if left untreated [1]. This
73 article focuses on the cost of vector control, one of the approaches to control the disease, by
74 reducing the population of tsetse flies responsible for transmitting the parasite [2].

75

76 By 1960, colonial authorities almost eliminated HAT, previously a major public health
77 problem affecting millions of people in Sub-Saharan Africa. This was achieved by
78 implementing –occasionally oppressive– case-finding measures and providing effective but
79 highly toxic treatments. Unfortunately, the disease re-emerged and peaked at the end of the
80 1990s, with over 30,000 new cases reported annually, causing a significant social and
81 economic impact on the affected regions. Stepping up HAT control and surveillance efforts
82 from the late 1990s onwards reversed this epidemiological trend, with around 6,200 cases
83 reported in 2013 [3].

84

85 Therefore, that year, the international community declared that HAT elimination was feasible
86 because of the sustained decrease in the disease burden, a better understanding of the
87 disease's epidemiology, and the prospect of improved diagnostics and treatment regimens that
88 were less toxic than previously. The World Health Organization (WHO) set 2020 as the
89 target date for HAT elimination as a public health problem, defined as reducing HAT
90 incidence to fewer than 1 new case per 10,000 population in at least 90% of foci and to fewer
91 than 2,000 cases reported globally. They also targeted 2030 as the year for disease

92 elimination, defined as zero disease incidence [2, 4-6]. In 2020, the elimination target was
93 largely achieved, with only 663 new HAT cases reported globally, 60% of which were
94 identified in the Democratic Republic of Congo (DRC) [7]. In 2022, 516 or 65% of the
95 gHAT cases reported globally were detected in the DRC [3].

96
97 Two forms of HAT exist in humans, caused by two subspecies of the parasite *Trypanosoma*
98 *brucei*, namely *T. b. gambiense* infections currently responsible for over 85% of all HAT
99 cases reported worldwide and *T. b. rhodesiense*. Both forms of HAT are targeted for
100 elimination as a public health problem, but only gambiense HAT (gHAT) is targeted for
101 elimination of transmission to humans as it is presumed to be an anthroponotic infection,
102 unlike *T. b. rhodesiense* HAT, which can infect animals [7].

103
104 gHAT is the only form of HAT present in the DRC, and HAT control in this context focuses
105 on clearing the parasite from humans [8]. This strategy is based on a multi-faceted approach,
106 focusing mainly on early case detection and treatment [2]. HAT diagnosis is difficult because
107 of its non-specific symptoms, the diagnostic algorithm's complexity, and the disease's focal
108 distribution [1]. Therefore, an exhaustive screening strategy, even with innovative diagnostics
109 and treatment, requires major investments in equipment, diagnostics, and human resources [2,
110 9]. Even though case-finding strategies have proven to be effective, there are still several foci
111 where transmission persists, sometimes even after HAT case detection and management has
112 been maintained for many years, most likely due to insufficient coverage of the population at
113 risk, limited sensitivity of diagnostic methods and the disappearing awareness and expertise
114 of medical staff [10, 11].

115

116 In the past, vector control methods, such as vegetation clearing, or insecticide spraying, and
117 in particular, trapping , were occasionally used to control gHAT but were often considered
118 ineffective, too expensive, or too complicated to implement in remote, resource-constrained
119 settings [12-15]. Today, a new, more straightforward and cost-effective method has been
120 developed to control populations of riverine tsetse that transmit *T. b. gambiense*, namely
121 'Tiny Targets'. These small, impregnated screens consist of one 25cm by 25cm square blue
122 cloth, flanked by an insecticide-impregnated mesh of the same size, deployed along the banks
123 of rivers and water bodies where tsetse concentrate. Tsetse are attracted by their blue colour
124 and contact the targets, picking up a lethal dose of insecticide. In 2011, Tiny Targets were
125 introduced in Guinea and Uganda where their relative entomological and economic cost-
126 effectiveness as compared to previous methods is discussed [16-18]. Afterwards, this
127 relatively cheap tool was effectively deployed in several other countries (e.g., Chad, Côte
128 d'Ivoire), achieving in all locations a decline in the tsetse population of 60-95% [19-21]. HAT
129 transmission models estimated that at least a 72% reduction in the tsetse population is
130 required to stop transmission and that the 2030 gHAT elimination goal would be achieved by
131 including a moderately effective tsetse control (60% tsetse population reduction) in the
132 overall gHAT control strategy. Therefore, vector control could be crucial in eliminating
133 gHAT cost-effectively [18, 22].

134

135 In 2015, gHAT vector control using Tiny Targets was implemented at the health district level
136 in the DRC for the first time. An evaluation of the impact of Tiny Targets on the *Glossina*
137 *fuscipes quanzensis*, the primary tsetse vector of gHAT in the DRC observed a reduction in
138 fly catches of more than 85% [13]. This study estimates the annual financial and economic
139 cost of Tiny Target deployment and identifies its main cost drivers.

140

141 **Materials and Methods**

142

143 **Research setting**

144 The health system of the DRC is organized at different levels, where every province is
145 subdivided into several health districts where a district team manages a network of health
146 centres and a district hospital. Each health district generally covers a human population
147 between 100,000 and 200,000 which according to national standards is subdivided into health
148 areas of around 10,000 inhabitants each, covered by at least one integrated health centre
149 [23].

150

151 As of 2014, a first project started in the health districts of Yasa Bonga and Mosango
152 focussing on improving HAT control named “Integrated HAT control, a model district in DR
153 Congo” and by the end of 2015 a second project was introduced in the same districts named
154 “TRYP-ELIM. A demonstration project combining innovative case detection, tsetse control
155 and IT to eliminate sleeping sickness at district level in the Democratic Republic of Congo”.
156 These projects aimed to effectively eliminate HAT transmission within three years from a
157 health district in the DRC through a combination of intensified systematic screening and case
158 management of at-risk populations with vector control. In the context of this project, tsetse
159 vector control with Tiny Targets (manufactured by Vestergaard, Lausanne, Switzerland) was
160 implemented throughout the HAT-endemic health district of Yasa Bonga in Kwilu province,
161 formerly Bandundu Province. Yasa Bonga is a rural health district with, in 2018, a total
162 population of 235,696 people scattered over 305 villages in an area of 2,810 km² [13, 24].
163 Over 45% of all HAT cases detected in the DRC were reported in the former Bandundu
164 between 2000 and 2012, with the highest annual incidence, of 40 cases/10,000 population
165 (208 new cases), being reported in Yasa Bonga. [25].

166


167 **Vector control with Tiny Targets in the study area**

168 Figure 1 shows the gradual scale up of vector control with Tiny Targets in the Yasa Bonga
169 health district along the riverbanks of some of the three main rivers (Lukula, Kafi, Inzia). In
170 2015, the rivers highlighted in red were treated, the following year the river to the north was
171 included as well, and in 2017 treatment was extended to include part of the river forming the
172 western border of the health district. Thus, by 2017, the health areas highlighted in green
173 were covered so that almost the whole health district was protected.

174

175 *Figure 1. Map showing the border of Yasa Bonga and the individual health areas. Overlain is the scaling up of vector*
176 *control in the health district of Yasa Bonga between 2015 and 2017 Map generated using QGIS 3.28.3 [26, 27]*

177



178

179

180

181

182 The deployments, as outlined in Table 1, occurred biannually during the dry seasons (July
183 and August and January/early February). To evaluate the impact of the Tiny Targets, the

184 abundance of tsetse flies was assessed before and after deployments. Pyramidal traps were
185 used to compare the number of flies captured during these periods [28]. Teams of day
186 workers without previous experience deployed the Tiny Targets. Local recruitment and
187 training were managed by the Programme National de Lutte contre la Trypanosomiase
188 Humaine Africaine (PNLTHA) and with support from entomologists from the PNLTHA and
189 the Liverpool School of Tropical Medicine (LSTM).

190

191 Teams assembled targets on-site by gluing the fabric on locally sourced wooden supports.
192 Using traditional canoes or "pirogues", the teams travelled down the river deploying the
193 targets aiming for 50-meter intervals on both riverbanks preferring shorter intervals when
194 exact 50m intervals were impossible due to unsuitable deployment or canoe docking sites,
195 explaining a higher actual number of targets deployed than the targeted 40targets/km. The
196 last deployment, covering the whole protected area, involved around 54 targets / linear km,
197 resulting in 11,311 targets over 210 linear km, as illustrated in S1. Annexe I. GPS points were
198 recorded for every target placed. Once a routine was established, the teams typically covered
199 around 40 linear km of river weekly (i.e., $40\text{km} \times 40 \text{ targets/km} = 1600 \text{ targets/week}$) though
200 this number increased over the years. A detailed description of the vector control intervention
201 and the impact on the vector, can be found in Tirados *et al.* [13]. S1. Annex II shows the
202 calendar with the different vector control activities during the study period including the
203 number of targets deployed and linear km treated per deployment during the scale up.
204 Awareness-building activities accompanied the vector control intervention to inform villages
205 about sleeping sickness and tsetse control activities. A vector control management unit was
206 set up at the provincial level after the study period in 2019, and this team manages a
207 standardized vector control sensitization strategy in all villages where vector control
208 measures are implemented. This strategy was used as a reference for the cost of awareness-

209 building activities in Yasa Bonga. In the health district, 165 villages that would be in contact
210 with the gHAT vector control were identified for sensitization. On average, the provincial
211 vector control team biennially trained three community health care workers per village.
212 Furthermore, a vector management control unit was set up at national level covering 11
213 health districts in 2 provinces. These costs were not taken into account in the main analysis
214 but their cost impact was assessed in the sensitivity analysis. Those community healthcare
215 workers were responsible for sensitizing other community healthcare workers and the local
216 population. They would receive T-shirts, a picture box, a banner, and megaphones, and their
217 work was supported with short broadcasts on local radio stations.

218

219 **Cost methodology**

220 The cost analysis adopted a provider's perspective focusing on costs incurred to implement
221 HAT vector control using Tiny Targets by the public health care system, namely the
222 PNLTHA. The study only considered costs related directly to the implementation of vector
223 control and omitted research costs as well as costs of geostatistical modeling before the
224 intervention to predict tsetse habitat distribution [29, 30]. A full costing approach was
225 adopted, which was the case for other similar analyses, as similar programs are assumed to be
226 implemented anew in different locations [17, 31, 32].

227

228 The study collected financial and economic costs at local prices between January 2015 and
229 September 2017 from routine activities, expense reports, budgets, and discussions with
230 experts. During this period, five target deployments took place, covering a gradually
231 expanding area, as shown in Figure 1 with the linear km treated and targets and traps used
232 detailed in S1. Annex 2.

233

234 These financial costs represent the monetary expenditures by PNLTHA directly associated
235 with the implementation of vector control. They encompass the tangible, measurable, and
236 explicit financial outlays required for the implementation of the activity. In contrast,
237 economic costs go beyond the explicit financial expenses and consider opportunity costs—
238 the value of resources that could have been used elsewhere but were allocated to vector
239 control and the value of unpaid inputs such as donated drugs or targets or unpaid local
240 community labour [33]. In this provider’s perspective study, as PNLTHA paid for all staff,
241 vehicles and other inputs into the control activity, there were not too many adjustments to be
242 made to convert from the financial to the economic viewpoint. For example, in this study
243 both staff and vehicles were employed full-time on the VC work, and none were shared with
244 other activities or were borrowed from other organisations as was the case in some of the
245 recent HAT vector control activities in other countries [31, 32]. However, some of the
246 management costs benefitted other activities.

247

248 The study considered resources with a useful life of less than 12 months as recurrent costs
249 and resources with a useful life of over a year as capital costs [34]. For the economic
250 analysis, the capital costs were annualized using straight line depreciation and assuming they
251 had no residual value at the end of this period. Thus their purchase value was divided by
252 their lifespan. Useful life estimates were based on discussions with experts and on WHO-
253 Choice guidelines [35].

254

255 A mixed-methods approach was used to estimate the annual costs to treat 210 linear km and
256 to protect 1,925 km², this being the ultimate extent of the whole operation after 5
257 deployments (Figure 1 and S1. Annexe II). Although PNLTHA was the sole implementer,
258 costs were recorded in different locations and at different levels of the organization. Thus,

259 bottom-up micro-costing was used to estimate costs that were directly allocated to target
260 deployment in the field. We collected detailed data on the quantities of inputs and prices to
261 value the resources used. Additionally, we used a step-down or gross costing approach to
262 estimate costs that could not directly be attributed to specific field activities, such as
263 management and transport costs [36]. The current awareness-building and management
264 strategy were costed using information from current activities (2018-2019), as a standardized
265 strategy for these activities was only implemented after the study period. The management
266 support unit at the provincial level accompanied the vector control activities in four health
267 districts, including Yasa Bonga. Therefore, in the economic analysis, the annual cost of
268 management support was divided by four to calculate the management costs attributable to
269 the health district of Yasa Bonga.

270
271 A 5-year period was selected for estimating the financial costs for treating the whole area,
272 with the aim of showing what the provider's costs over time would be for funding such an
273 operation. The time period chosen reflected that capital equipment with the highest cost,
274 namely the vehicles, was determined to have the longest estimated lifespan of 5 years
275 according to discussions with field experts. Thus, we took the costs collected for the actual
276 operation and put them together to show how a 5-year project would look. Then, we made
277 the appropriate adjustments for converting them to economic costs as explained above,
278 replacing capital costs with annual depreciation and adjusting the share of management costs.
279 These costs were not discounted as we only looked at the cost of one year of vector control
280 deployment.

281
282 Afterwards, the results were combined to calculate the total annual cost to implement tsetse
283 control covering the entire health district and the cost per activity, namely entomological

284 monitoring and surveillance, sensitization, biannual target deployment, and management
285 support costs. The costs were presented in four main categories: human resources (HR),
286 transport-related costs (fuel, vehicle use and maintenance, and rent of pirogue), specialized
287 equipment, and other (stationary, small camping equipment, etc.) [17, 31, 32]. Then we
288 looked at the main cost drivers, namely specific expenses that significantly influenced or
289 contributed to the overall costs.

290

291 In order to be able to compare the results from Yasa Bonga with gHAT vector control using
292 Tiny Targets in other settings, the cost was also expressed as a cost per (i) area protected
293 (USD/ km²), (ii) cost per target used (USD/target - accounting for the number of targets used
294 annually to protect the area), (iii) target deployed (USD/target - factoring in the number of
295 targets deployed in the protected area), (iv) length of river controlled (USD/km), and person
296 protected (USD/person). We performed a univariate sensitivity analysis for the economic cost
297 of the main cost drivers to evaluate the impact of these drivers on the overall costs. This
298 analysis included considering annual and triannual sensitization, varying the transport costs
299 (+- 10%), including the cost of the vector control unit at central level and varying the number
300 of health districts management by a vector control unit at provincial level. Lastly, the results
301 were compared with cost estimates of vector control with Tiny Targets in other settings.

302

303 All costs were recorded in the currency in which they were incurred and converted to USD
304 using the average exchange rate between January 2015 and September 2017, which were
305 Euro to dollar: 1.13 and Congolese franc (CDF) to dollar: 0.00084.

306

307 **Results**

308
 309 Over this 5-year period, the projected annual financial costs for covering the whole area
 310 protected by the end of 2017 would thus range from 104,630 USD to 168,478 USD, with the
 311 highest cost in the first year reflecting the initial capital investments required, as illustrated in
 312 Table 1. Sensitization and management support costs would be highest in the first year, while
 313 costs associated with monitoring, surveillance, and target deployment remained consistent
 314 across the years. The number of targets deployed increased between 2015 and 2017,
 315 correlating with the expanded linear coverage, as illustrated in Figure 1. For a detailed
 316 breakdown of yearly costs during the scale-up, refer to S1.Annex III. The overall financial
 317 cost over the 5-year period is projected to decrease by approximately 113,000 USD or almost
 318 20% if the targets are donated by the manufacturer.

319
 320 *Table 1 Estimated financial cost of the full scale intervention for a 5-year period based on the costs reported between 2015*
 321 *and 2017 (USD).*

Description/cost category	Total Y1	Total Y2	Total Y3	Total Y4	Total Y5	Total Y1-Y5
Monitoring/Surveillance	14,214	14,214	14,214	14,214	14,214	71,071
Sensitization	44,217	19,541	27,717	19,541	27,717	138,731
Biannual target deployment	57,571	57,571	57,571	57,571	57,571	287,855
Management support costs	52,476	13,305	13,780	13,755	19,286	112,601
Total cost	168,478	104,630	113,282	105,080	118,788	610,257
Cost Tiny targets (1\$)	22,622	22,622	22,622	22,622	22,622	113,110
Total cost with Tiny target donation	145,856	82,008	82,008	82,458	96,166	497,147

322

323 As illustrated in Table 2, the total average annual economic cost for vector control in the
 324 health district of Yasa Bonga to treat 210 linear km is 120,127 USD. Almost 50% of the cost
 325 is linked to the biannual target deployment, and the management and sensitization each
 326 represent around 20% of the costs (see Figure 2). The cost per target used was estimated at
 327 5.31 USD, 573 USD per linear km of river treated, or 62.4 USD per km² protected. Costs that
 328 could not directly be attributed to a specific category were reported under "Other," such as
 329 glue to assemble the targets, camping equipment, phone, and internet credit. How financial
 330 costs were converted into economic costs is shown in S2.Supplementary Spreadsheet and
 331 S1.Annex III also details the cost per deployment and monitoring and surveillance round.

332

333 *Table 2 Estimated average annual economic cost to cover 210 linear km based on the costs reported between 2015 and 2017*

334 *(USD). Calculations are shown in the S2.Supplementary Spreadsheet.*

Activity/ Cost category	Total USD	%
Monitoring/Surveillance	14,214	12
HR	2,610	2
Transport	5,443	5
Traps	4,189	3
Other	1,972	2
Sensitization	26,929	22
HR	2,888	2
Transport	-	0
Specialized equipment	15,964	13
Other	8,077	7

Biannual target deployment	57,571	48
Tiny Targets	26,399	22
HR	14,016	12
Transport	10,198	8
Other	6,959	6
Management support costs	21,413	18
HR	10,345	9
Transport	9,035	8
Specialized equipment	-	0
Other	657	1
Trainings/meetings	1,317	1
Total cost	120,127	100
<hr/>		
Cost per target used (22,622)	5.31	
Cost per target deployed (11,311)	10.62	
Cost per linear km (210)	573	
Cost per km² protected (1,925)	62.4	

335


336 The main cost drivers are the purchase and import of Tiny Targets and traps (29%), human
 337 resources during the deployment and monitoring (16%), sensitization equipment (15%) and
 338 fuel (12%) (Figure 3). This is also reflected in the breakdown of the costs per activity as
 339 shown in Figure 2.

340

341

342 *Figure 2 Contribution of the different activities to the overall annual economic cost (in 1,000 USD)*

343




344

345

346

347 *Figure 2 Contribution of the main cost drivers in relation to the different categories (in 1,000 USD)*

348



349

350


351 Sensitivity analysis

352 The sensitivity analysis looked at changes in the main cost drivers on the economic cost per
 353 km² and the economic cost per linear km of vector control deployed (Figures 4-5). Changes
 354 in the transport cost had a minor impact on the overall cost. The cost would decrease by 10%
 355 if the sensitisation would take place once every three years instead of biannually. The most


356 significant impact on the cost can be seen in the coverage of the management unit, namely
 357 the number of health districts the current set-up of the management unit could accompany
 358 and supervise. Setting up such a unit for a limited number of health districts would drastically
 359 increase the overall cost of vector control. On the other hand, the cost would decrease if
 360 health districts could independently deploy vector control with limited strategic support from
 361 the provincial level so these resources could be used to cover a larger area but this could also
 362 negatively impact the quality and traceability of the intervention. If a provincial unit were
 363 able to cover 20 health districts the overall cost would decrease with 55%.

364
 365 Furthermore, the estimated cost did not take into account the cost of the vector control
 366 management unit at central level that supports 11 health districts in 2 provinces. Including
 367 this cost would increase the overall cost by approximately 6%.

369 *Figure 3 Sensitivity analysis – Economic cost per km² protected*



371 *Figure 4 Sensitivity analysis – Economic cost per linear km*



374 **Comparison of cost of HAT vector control using Tiny Targets in other settings**

375 Lastly, in Table 3, we look at the cost of the work in Yasa Bonga, compared to the costs
376 calculated for the three other Tiny Target costed [17, 31, 32]. The cost comparisons vary
377 greatly depending on which criterion used. The annual cost per target deployed is much lower
378 than in other countries, while the cost per area controlled (USD/km²) is similar to Arua,
379 Uganda, and Mandoul, Chad. A comparable cost to Chad was observed for the cost per km²
380 protected. Still, since Yasa Bonga is more densely populated than Mandoul, the intervention
381 was cheaper regarding cost per person protected, yielding a value similar to that in Côte
382 d'Ivoire. One of the reasons for the lower annual cost per target deployed in Yasa Bonga and
383 Uganda, compared to Chad and Côte d'Ivoire is due to the organizational context. Activities
384 in the DRC are done by locally recruited staff supervised by provincial management teams
385 resulting in lower salary costs and lower costs related to supervision visits (per diem,
386 transport, etc.)

387 *Table 3 Comparison of annual vector control activities and costs in different settings*

Description (costs in USD)	Chad	Côte D'Ivoire	Uganda	DRC
	2015-2016 [21, 31, 32]	2016-2017 ¹ [19, 31]	2012-2013 ² [17, 18, 31]	2015-2017 ³ [13]
Annual economic cost	56,133	61,253	21,982	120,127
Number of targets deployed in the area covered	2,708	1,939	1,551	11,311
Target maintenance	Annual redeployment	Annual redeployment	60% redeployed in 2012/13	Biannual redeployment
Annual number of targets used in the covered area	2,708	1,939	2,501	22,622
Annual cost per target deployed in the area covered	21	32	14	11
Number of linear km treated	45	NA	78	210
Targets per linear km	60	NA	20	54
Annual cost per linear km treated	1,244	NA	283	573
Number of km ² treated	45	130	16	NA
Targets per km ² treated	60	15	97	NA
Annual cost per km² treated	1,247	471	1,374	NA
Number of km ² protected	840	130	250	1,925
Targets per km ² protected	3	15	6	6

Annual cost per km² protected	67	471	88	62
Number of people protected	39,000	120,000	112,500	165,062
Population density (person/km ² protected)	46	923	400-500	86
Annual cost per person protected	1.44	0.51	0.20	0.73

388 ¹ NA – Not applicable as Tiny Targets were deployed throughout the intervention area.

389 ² Costs were converted to 2016 prices [31]. Half way through year 2012-13 for which the costs were analysed,
 390 about 60% of targets were replaced. In subsequent years, Uganda moved to biannual redeployment as in
 391 DRC. The number of people protected in Uganda was estimated at between 100,000 and 125,000.

392 ³ NA – Not applicable as Tiny Targets were deployed on the narrow fringing vegetation of the rivers.

393

394 Discussion

395 This study estimates the costs of vector control for HAT using Tiny Targets in the DRC. At a
 396 total economic cost of 120,127 USD or a financial cost ranging between 104,630 USD and
 397 168,478 USD per annum for protecting an area of 1,925 km, depending on the assumptions
 398 made, the cost per person protected comes to 0.73 USD or 11 USD per target deployed. At
 399 the beginning of the Tiny Target operation, financial costs are driven by sensitization and
 400 management, after which target deployment dominates the costs. In terms of the average
 401 annual economic costs, almost 50% are attributed to deployment, and 20% each to
 402 management and sensitization. Monitoring and surveillance account for the lowest proportion
 403 of costs, both in economic and financial terms. Currently the Tiny Targets are donated by the
 404 manufacturer which is projected to reduce the financial cost by almost 20%.

405

406 In this paper we have emphasized both the costing methodology and the nature and detail of
407 the information required. Our objective was to help enable such cost analyses of vector
408 control work to be conducted in other settings, not just retrospectively, at the evaluation stage
409 but also before work is undertaken, when first planning an intervention. Thus, S1.Annexes
410 contains not just details supporting the calculations presented above, but also of the
411 individual components of the deployment, trap monitoring and sensitisation costs. More
412 information is available in the S2.Supplementary spreadsheet. The basic methodology of
413 collecting financial costs and adjusting these to better reflect the total economic or societal
414 cost has been explored to some extent in the previous papers on the cost of Tiny Target
415 operations to control HAT transmission but here we emphasize and contrast the two
416 approaches [17, 31, 32].

417
418 Assessing the cost-effectiveness of tsetse control is challenging due to the complexity of
419 factors influencing vector control costs and effects. A comparison of results for the DRC with
420 those from other countries suggests significant variations in vector control costs. In HAT
421 endemic foci, adapting vector control strategies to the local context is essential, introducing
422 variability in the overall costs. Numerous factors contribute to this variability, including
423 diverse tsetse habitats such as expansive forests, mangroves, swamps, and narrow linear
424 riverbanks. Further the choice of vector control strategy hinges on considerations such as
425 target coverage, deployment methods (ranging from canoes and on-foot approaches to the use
426 of cars and motorbikes), the availability of local manpower and the frequency of target
427 deployment and monitoring. All these factors contribute to the intricacies of the overall cost.

428
429 Defining the effectiveness of vector control for sleeping sickness involves evaluating its
430 impact on reducing disease transmission by tsetse flies, primarily with the preventive

431 objective of mitigating and ideally halting HAT transmission. In contrast, other HAT control
432 measures, namely case detection and subsequent treatment, operate reactively by addressing
433 cases post-infection. Vector control efficacy could be measured by the reduction in cases or
434 the number of cases averted. The prevalence of the disease within a protected area will
435 significantly influence the effectiveness, measured in terms of cases averted or Disability-
436 Adjusted Life Years (DALYs) avoided.

437

438 Directly comparing the cost-effectiveness of a vector control intervention is challenging, as it
439 is seldom the only control measure implemented and it's difficult to measure it's impact on
440 transmission. Therefore, the cost-effectiveness of vector control is typically expressed in
441 metrics like cost per km treated, cost per km² protected, or cost per population protected (or
442 cost per case averted when feasible). However, these indicators are influenced by factors
443 external to the vector control intervention, such as baseline prevalence, population density in
444 the protected area, or the size of the protected area compared to the treated area. Therefore, it
445 is crucial to consider the denominator when interpreting the cost-effectiveness indicators
446 presented in this paper. Vector control with Tiny Targets appears to be more cost-effective in
447 terms of cost per person protected in Uganda, Côte d'Ivoire, and the DRC as the tool was
448 deployed in an area with a higher population density, resulting in a relatively lower cost per
449 person protected than in Chad [17, 31, 32].

450

451 For sleeping sickness, an optimal strategy would likely integrate case detection initiatives
452 aimed at promptly identifying and treating infected individuals with vector control methods
453 targeting the reduction of tsetse fly transmission. The collaborative impact of these
454 approaches synergizes to most likely yield a substantial reduction in sleeping sickness cases.
455 The evaluation of their individual and combined effectiveness and costs is the focus of the

456 Human African Trypanosomiasis Modeling and Economic Predictions for Policy (HAT
457 MEPP) project [37].

458

459 While several studies demonstrated that vector control of tsetse flies can play an essential
460 role in HAT elimination, using Tiny Targets presents several limitations and challenges.

461 Significantly reducing the HAT disease burden through tsetse control relies on its ability to

462 reduce transmission effectively. HAT tends to persist in remote and rural areas with dense

463 vegetation near water sources such as rivers, lakes, and ponds. The lack of comprehensive,

464 accurate geospatial data on tsetse fly habitats, along with limited information about the actual

465 "transmission zones," the sites where people get bitten by infected tsetse, makes it

466 challenging to identify locations where vector control could impact transmission. This

467 requires geospatial modelling followed by on-site entomological surveys, but limited

468 information is available on the complete actual cost of these preliminary evaluations [17, 30-

469 32]. These knowledge gaps also make it challenging to develop a uniform vector control

470 strategy or to determine the necessary "quantity" of vector control per square kilometer

471 needed to halt transmission throughout the countries affected by the disease [19, 38].

472

473 Additionally, an exploratory entomological survey in Yasa Bonga conducted in the same

474 period as the study on community-based control of tsetse ('17-'18) revealed that fishponds

475 provided suitable habitats for tsetse. Nevertheless, covering these areas with large-scale

476 vector control interventions led by individuals not familiar with the local environment is

477 challenging due to the difficulty in locating and navigating such areas, which would

478 significantly increase the workload of the vector control teams. A study in the southwest of

479 the health district (see Figure 1) showed that these areas could be covered with a community-

480 based approach to Tiny Targets deployment, organized and managed by local community

481 members. However, data available on the costs for this type of intervention is currently
482 unavailable [39].

483

484 Currently, the DRC vector control for sleeping sickness is successfully being implemented by
485 local teams managed by the PNLTHA. This is taking place in a select number of health
486 districts located in provinces adjacent to the Kinshasa province and accessible by car from
487 the capital. The activities were successfully continued during the COVID-19 pandemic,
488 which shows that a sustainable system was developed that transitioned responsibilities to
489 provincial and health district levels [40]. Introducing vector control activities in remote and
490 resource-constrained areas in other provinces of the DRC will require additional investment
491 for the preliminary geospatial and entomological studies needed, the creation of vector
492 control capacity (resource, equipment, and trained personnel, etc.) and higher transport costs,
493 compared to Bandundu, due to the distances and a higher fuel cost. Initial costs related to
494 training, infrastructure development, and equipment acquisition would be spread over a
495 shorter duration if the intervention would be implement for a limited period due to the
496 context of disease elimination resulting in a higher average cost. HAT vector control might
497 leverage an existing supply chain and management system by integrating this activity into the
498 broader health system while reinforcing the entire health system beyond this specific disease
499 focus.

500

501 Vector control using Tiny Targets has proven to be a feasible tool at a lower cost than former
502 methods [41]. Therefore, Tiny Targets can play an important role in the HAT elimination
503 strategy as it could help stop transmission in foci where the disease persists. The successful
504 scale-up of a Tiny Targets will require a good local understanding of the terrestrial and
505 aquatic ecosystem of tsetse fly habitats and the development of tsetse control measures where

506 provincial and health district levels play an important role. The implementation cost of this
507 approach can be drastically reduced when implemented on a large scale, with a local vector
508 control management unit covering a larger geographical area for minimum duration of 5
509 years, allowing full use of the investments needed to build local capacity and awareness.
510 While any measure aimed at elimination will present some challenges, this study, like other
511 costing studies on Tiny Targets, shows that the cost can be quite accessible.

512

513

514 **Acknowledgments**

515 The authors acknowledge the staff of the PNLTHA and the fieldworkers in Yasa Bonga for
516 their contributions under arduous field conditions. The authors also would like to thank
517 Professor Stephen Torr and Dr. Andrew Hope for their valuable contributions to the final
518 draft of the article.

519

520 **Declaration of interests**

521 The authors declare that they have no competing interests.

522

523 **Role of the funding source**

524 This study was funded by the Bill & Melinda Gates Foundation (grant OPP1155293) and the
525 Margaret A. Cargill Foundation within the framework of 2 projects aiming to eliminate HAT
526 in two health districts in the Democratic Republic of Congo. The funders had no role in the
527 study design, data collection, analysis, or article publication. Human African
528 Trypanosomiasis Modelling and Economic Predictions for Policy (HAT MEPP) project
529 [OPP1177824 and INV- 005121] supported MA and FT.

530

531

532

533 **References**

534

535

536 1. Buscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis.

537 Lancet (London, England). 2017;390(10110):2397-409. Epub 2017/07/05. doi:

538 10.1016/s0140-6736(17)31510-6. PubMed PMID: 28673422.

539 2. World Health Organization (WHO). Factsheet: Trypanosomiasis, human African

540 (sleeping sickness) Geneva: WHO; 2023 [updated 02/05/2023 Cited on 21/08/2023].

541 Available from: [https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness))

542 [african-\(sleeping-sickness\)](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)).

543 3. World Health Organization (WHO). Global Health Observatory data repository:

544 Number of new reported cases (T.b. gambiense):2022 Geneva: WHO; 2023 [updated

545 19/06/2023 07/11/2023]. Available from:

546 <https://apps.who.int/gho/data/node.main.A1636?lang=en>.

547 4. Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African

548 trypanosomiasis. Clin Epidemiol. 2014;6:257-75. doi: 10.2147/CLEP.S39728. PubMed

549 PMID: 4130665.

550 5. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. The journey towards

551 elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology.

552 2014;141(6):748-60. Epub 2014/01/28. doi: 10.1017/S0031182013002102.

553 6. World Health Organization (WHO). Accelerating work to overcome the global impact

554 of Neglected tropical diseases: A Roadmap for implementation (WHO/HTM/NTD/2012.1).

555 Geneva: WHO, 2012.

556 7. Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Kadima Ebeja A, et al. The

557 elimination of human African trypanosomiasis: Achievements in relation to WHO road map

- 558 targets for 2020. PLOS Neglected Tropical Diseases. 2022;16(1):e0010047. doi:
559 10.1371/journal.pntd.0010047.
- 560 8. Büscher P, Bart JM, Boelaert M, Bucheton B, Cecchi G, Chitnis N, et al. Do Cryptic
561 Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? Trends Parasitol.
562 2018;34(3):197-207. Epub 20180123. doi: 10.1016/j.pt.2017.11.008. PubMed PMID:
563 29396200; PubMed Central PMCID: PMC5840517.
- 564 9. Steinmann P, Stone CM, Sutherland CS, Tanner M, Tediosi F. Contemporary and
565 emerging strategies for eliminating human African trypanosomiasis due to *Trypanosoma*
566 *brucei gambiense*: review. Tropical Medicine & International Health. 2015;20(6):707-18.
567 Epub 2015/02/20. doi: 10.1111/tmi.12483. PubMed PMID: 25694261.
- 568 10. Mpanya A, Hendrickx D, Baloji S, Lumbala C, Luz RI, Boelaert M, et al. From health
569 advice to taboo: community perspectives on the treatment of sleeping sickness in the
570 Democratic Republic of Congo, a qualitative study. PLoS Neglected Tropical Diseases.
571 2015;9(4):e0003686. Epub 2015/04/10. doi: 10.1371/journal.pntd.0003686. PubMed PMID:
572 25856578; PubMed Central PMCID: PMC4391751.
- 573 11. Solano P, Torr SJ, Lehane MJ. Is vector control needed to eliminate gambiense
574 human African trypanosomiasis? Front Cell Infect Microbiol. 2013;3. Epub 2013/08/06. doi:
575 10.3389/fcimb.2013.00033. PubMed Central PMCID: PMC3728477.
- 576 12. World Health Organization (WHO). Control and surveillance of *human African*
577 *trypanosomiasis*, WHO technical report series (984). Geneva: WHO, 2013 0512-3054 (Print)
578 0512-3054 Contract No.: 984.
- 579 13. Tirados I, Hope A, Selby R, Mpembele F, Miaka EM, Boelaert M, et al. Impact of
580 tiny targets on *Glossina fuscipes quanzensis*, the primary vector of human African
581 trypanosomiasis in the Democratic Republic of the Congo. PLOS Neglected Tropical
582 Diseases. 2020;14(10):e0008270. doi: 10.1371/journal.pntd.0008270.

- 583 14. Simarro PP, Sima FO, Mir M, Mateo MJ, Roche J. La lutte contre la trypanosomiase
584 humaine africaine
585 dans le foyer de Luba en Guinee equatoriale: bilan
586 de trois methodes. Bulletin of the World Health Organization. 1991;69(4):451-7. PubMed
587 PMID: 1934239; PubMed Central PMCID: PMCPMC2393243.
- 588 15. Challier A, Laveissiere C. La lutte contre les vecteurs de la maladie du sommeil à
589 Trypanosoma gambiense Dutton. Med Trop (Mars). 1978;38(6):697-703. PubMed PMID:
590 745535.
- 591 16. Courtin F, Camara M, Rayaisse JB, Kagbadouno M, Dama E, Camara O. Reducing
592 human-tsetse contact significantly enhances the efficacy of sleeping sickness active screening
593 campaigns: A promising result in the context of elimination. PLoS Neglected Tropical
594 Diseases. 2015;9. doi: 10.1371/journal.pntd.0003727.
- 595 17. Shaw APM, Tirados I, Mangwiroti CTN, Esterhuizen J, Lehane MJ, Torr SJ, et al.
596 Costs of using “tiny targets” to control glossina fuscipes fuscipes, a vector of gambiense
597 sleeping sickness in Arua district of Uganda. PLoS Neglected Tropical Diseases.
598 2015;9(3):e0003624. doi: 10.1371/journal.pntd.0003624.
- 599 18. Tirados I, Esterhuizen J, Kovacic V, Mangwiroti TNC, Vale GA, Hastings I, et al.
600 Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. PLOS
601 Neglected Tropical Diseases. 2015;9(8):e0003822. doi: 10.1371/journal.pntd.0003822.
- 602 19. Kaba D, Djohan V, Berté D, Ta BT, Selby R, Kouadio KADM, et al. Use of vector
603 control to protect people from sleeping sickness in the focus of Bonon (Côte d’Ivoire). PLOS
604 Neglected Tropical Diseases. 2021;15(6):e0009404. doi: 10.1371/journal.pntd.0009404.
- 605 20. Hope A, Mugenyi A, Esterhuizen J, Tirados I, Cunningham L, Garrod G, et al.
606 Scaling up of tsetse control to eliminate Gambian sleeping sickness in northern Uganda.
607 PLoS Negl Trop Dis. 2022;16(6):e0010222. Epub 20220629. doi:

- 608 10.1371/journal.pntd.0010222. PubMed PMID: 35767572; PubMed Central PMCID:
609 PMC9275725.
- 610 21. Mahamat MH, Peka M, Rayaisse JB, Rock KS, Toko MA, Darnas J, et al. Adding
611 tsetse control to medical activities contributes to decreasing transmission of sleeping sickness
612 in the Mandoul focus (Chad). PLoS Negl Trop Dis. 2017;11(7):e0005792. Epub 20170727.
613 doi: 10.1371/journal.pntd.0005792. PubMed PMID: 28750007; PubMed Central PMCID:
614 PMC5549763.
- 615 22. Rock KS, Torr SJ, Lumbala C, Keeling MJ. Predicting the Impact of Intervention
616 Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic
617 Republic of Congo. PLoS Negl Trop Dis. 2017;11(1):e0005162. Epub 20170105. doi:
618 10.1371/journal.pntd.0005162. PubMed PMID: 28056016; PubMed Central PMCID:
619 PMC5215767.
- 620 23. World Health Organization (WHO). Improving health system efficiency: Democratic
621 Republic of the Congo: improving aid coordination in the health sector. Geneva: World
622 Health Organization, 2015 2015. Report No.: Contract No.:
623 WHO/HIS/HGF/CaseStudy/15.4.
- 624 24. Mubwa Mungwele N. Rapport annuel 2017: Yasa Bonga. Yasa Bonga: 2018.
- 625 25. PNLTHA. Database HAT cases: 2013 - 2017. In: PNLTHA, editor. Kinshasa,
626 DRC2017.
- 627 26. DIVA-GIS. DIVA-GIS - Download data by country - Country: Congo, The
628 Democratic Republic of the; Subject: Administrative areas: DIVA-GIS; 2023 [10/07/2023].
629 Available from: <https://www.diva-gis.org/gdata>.
- 630 27. QGIS Development Team. QGIS Geographic Information System. 3.28.9-Firenze ed:
631 QGIS Association; 2023.

- 632 28. Gouteux JP, Lancien J. The pyramidal trap for collecting and controlling tsetse flies
633 (Diptera: Glossinidae). Comparative trials and description of new collecting technics. Trop
634 Med Parasitol. 1986;37(1):61-6. PubMed PMID: 3704477.
- 635 29. Garrison LP, Jr., Pauly MV, Willke RJ, Neumann PJ. An Overview of Value,
636 Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task
637 Force Report [2]. Value Health. 2018;21(2):124-30. Epub 2018/02/27. doi:
638 10.1016/j.jval.2017.12.006. PubMed PMID: 29477389.
- 639 30. Stanton MC, Esterhuizen J, Tirados I, Betts H, Torr SJ. The development of high
640 resolution maps of tsetse abundance to guide interventions against human African
641 trypanosomiasis in northern Uganda. Parasit Vectors. 2018;11(1):340. Epub 20180608. doi:
642 10.1186/s13071-018-2922-5. PubMed PMID: 29884213; PubMed Central PMCID:
643 PMC5994020.
- 644 31. Courtin F, Kaba D, Rayaisse J-B, Solano P, Torr SJ, Shaw APM. The cost of tsetse
645 control using 'Tiny Targets' in the sleeping sickness endemic forest area of Bonon in Côte
646 d'Ivoire: Implications for comparing costs across different settings. PLOS Neglected Tropical
647 Diseases. 2022;16(1):e0010033. doi: 10.1371/journal.pntd.0010033.
- 648 32. Rayaisse JB, Courtin F, Mahamat MH, Chérif M, Yoni W, Gadjibet NMO, et al.
649 Delivering 'tiny targets' in a remote region of southern Chad: a cost analysis of tsetse control
650 in the Mandoul sleeping sickness focus. Parasit Vectors. 2020;13(1):419. Epub 20200814.
651 doi: 10.1186/s13071-020-04286-w. PubMed PMID: 32795375; PubMed Central PMCID:
652 PMC7427721.
- 653 33. Drummond MF, Sculpher M, Claxton K, Stoddard GL, Torrance G. Methods for The
654 economic evaluation of health care programmes fourth edition: Oxford; 2015.
- 655 34. Creese AP, D. Cost analysis in primary health care : a training manual for programme
656 managers. Geneva: World Health Organization. 1995.

- 657 35. World Health Organization (WHO). CHOosing Interventions that are Cost Effective
658 (WHO-CHOICE): Table 4: Capital Item - Useful Lives Reported by Country Experts
659 Geneva: WHO; 2008 [cited 2018]. Available from:
660 https://www.who.int/choice/costs/prices_t4/en/.
- 661 36. Conteh L, Walker D. Cost and unit cost calculations using step-down accounting.
662 Health policy and planning. 2004;19(2):127-35. Epub 2004/02/26. PubMed PMID:
663 14982891.
- 664 37. Rock KS, Huang C-I, Crump RE, Brown PE, Antillon M, Crowley EH, et al. HAT
665 Modelling and Economic Predictions for Policy (HAT MEPP) 2023 [updated
666 28/11/202318/01/2024]. Available from:
667 https://warwick.ac.uk/fac/cross_fac/zeeman_institute/new_research/combating_disease/hat/hatmepp/.
- 668
- 669 38. Rayaisse JB, Esterhuizen J, Tirados I, Kaba D, Salou E, Diarrassouba A, et al.
670 Towards an optimal design of target for tsetse control: Comparisons of novel targets for the
671 control of palpalis group tsetse in west Africa. PLoS Neglected Tropical Diseases.
672 2011;5(9):e1332. doi: 10.1371/journal.pntd.0001332.
- 673 39. Vander Kelen C, Mpanya A, Boelaert M, Miaka E, Pérez Chacón D, Pulford J, et al.
674 Feasibility of community-based control of tsetse: A pilot project using Tiny Targets in the
675 Democratic Republic of Congo. PLoS Negl Trop Dis. 2020;14(9):e0008696. Epub 20200924.
676 doi: 10.1371/journal.pntd.0008696. PubMed PMID: 32970689; PubMed Central PMCID:
677 PMC7537905.
- 678 40. Abomo P, Miaka EM, Crossman SJ, Hope A. Demonstrating the sustainability of
679 capacity strengthening amidst COVID-19. Int Health. 2021;13(5):480-1. doi:
680 10.1093/inthealth/ihab004. PubMed PMID: 33594422; PubMed Central PMCID:
681 PMCPMC7928908.

- 682 41. WHO Fa. Vector control and the elimination of gambiense human African
683 trypanosomiasis (HAT) -
684 Joint FAO/WHO Virtual Expert Meeting - 5-6 October 2021. Rome: 2022.
685
686